Evidence map›Paper›PMID 28973417›Full record

ArticleNeurosurgery2018

Thalamic Glioblastoma: Clinical Presentation, Management Strategies, and Outcomes.

Yoshua Esquenazi, Nelson Moussazadeh, Thomas W Link, Koos E Hovinga, Anne S Reiner, Natalie M DiStefano, Cameron Brennan, Philip Gutin, Viviane Tabar

Open access · greenAbstract read
In one paragraph

Article in Neurosurgery, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
33citing papers in PubMed, 1 pooled it
2.9field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

33 citing papers in PubMed, 1 synthesis or guideline pooled it, 58 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Yoshua EsquenaziVivian L. Smith Department of Neurosurgery, The University of Texas Health Science Center at Houston, Houston, Texas.
Nelson MoussazadehDepartment of Neurosurgery, New York Presbyterian Hospital-Weill Cornell Medical Center, New York, New York.
Thomas W LinkDepartment of Neurosurgery, New York Presbyterian Hospital-Weill Cornell Medical Center, New York, New York.
Koos E HovingaDepartment of Neurosurgery, Memorial Sloan Kettering Cancer Center, New York, New York.
Anne S ReinerDepartment of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York.
Natalie M DiStefanoDepartment of Neurosurgery, Memorial Sloan Kettering Cancer Center, New York, New York.
Cameron BrennanDepartment of Neurosurgery, Memorial Sloan Kettering Cancer Center, New York, New York.
Philip GutinDepartment of Neurosurgery, Memorial Sloan Kettering Cancer Center, New York, New York.
Viviane TabarDepartment of Neurosurgery, Memorial Sloan Kettering Cancer Center, New York, New York.
New York Hospital Queens · USMemorial Sloan Kettering Cancer Center · USCornell University · US

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4M
NCI NIH HHS P30 CA008748
6 · The paper itself

Abstract

backgroundThalamic glioblastomas (GBMs) represent a significant neurosurgical challenge. In view of the low incidence of these tumors, outcome data and management strategies are not well defined.

objectiveTo identify the natural history and factors associated with survival in patients with thalamic glioblastoma.

methodsA retrospective review of all patients with thalamic glioblastoma over a 10-yr period was performed. Presenting clinical, radiological, and outcome data were collected. Chi-squared and Fisher's exact tests were used to compare clinical characteristics across tumor groups. Cox proportional hazard models were utilized to investigate variables of interest with regard to overall survival.

resultsFifty-seven patients met inclusion criteria, with a median age of 53 and median Karnofsky Performance Scale (KPS) score of 80. The most common presenting symptoms were weakness, confusion, and headache. Hydrocephalus was present in 47% of patients preoperatively. Stereotactic biopsy was performed in 47 cases, and 10 patients underwent craniotomy. The median overall survival was 12.2 mo. Higher KPS, younger age, and cerebrospinal fluid (CSF) diversion were correlated with better overall survival univariately, respectively, while the presence of language deficits at initial presentation was associated with poorer survival. In multivariate analysis, the only significant predictor of survival was presenting KPS.

conclusionThe overall survival of patients with thalamic glioblastoma is comparable to unresectable lobar supratentorial GBMs. Younger patients and those with good presenting functional status had improved survival. Midbrain involvement by the tumor is not a negative prognostic factor. Improved therapies are needed, and patients should be considered for early trial involvement and aggressive upfront therapy.

Indexed as

AdolescentAdultAgedAged, 80 and overBrain NeoplasmsFemaleGlioblastomaHumansMiddle AgedProportional Hazards ModelsRetrospective StudiesTreatment OutcomeYoung Adult

Identifiers

PMID28973417
PMCPMC6939410
OpenAlexW2737338166

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.